Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/57798

Type
Preprint
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

LONGITUDINAL EVALUATION OF ANTIBODY PERSISTENCE IN MOTHER-INFANT DYADS FOLLOWING SARS-COV-2 INFECTION IN PREGNANCY
Cambou, Mary C. et al. | Date Issued: 2022
Author
Cambou, Mary C.
Liu, Christine M.
Mok, Thalia
Fajardo-Martinez, Viviana
Paiola, Sophia G.
Ibarrondo, Francisco J.
Kerin, Tara
Fuller, Trevon
Tobin, Nicole H.
Garcia, Gustavo
Bhattacharya, Debika
Aldrovandi, Grace M.
Arumugaswami, Vaithilingaraja
Suan-Sin, Foo
Jung, Jae U.
Vasconcelos, Zilton
Brasil, Patricia
Brendolin, Michelle
Yang, Otto
Rao, Rashmi
Nielsen-Saines, Karin
Affilliation
University of California. David Geffen School of Medicine. Department of Medicine. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Medicine. Los Angeles, California, USA.
University of California. Department of Obstetrics and Gynecology. David Geffen School of Medicine. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Medicine. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Doenças Febris Agudas. Rio de Janeiro, RJ, Brasil.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA.
University of California. Department of Molecular and Medical Pharmacology. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Medicine. Los Angeles, California, USA.
University of California. Department of Obstetrics and Gynecology. David Geffen School of Medicine. Los Angeles, California, USA.
University of California. Department of Molecular and Medical Pharmacology. Los Angeles, California, USA.
Department of Cancer Biology. Infection Biology Program and Global Center for Pathogen and Human Health Research Cleveland Clinic. Cleveland, Ohio, USA.
Department of Cancer Biology. Infection Biology Program and Global Center for Pathogen and Human Health Research Cleveland Clinic. Cleveland, Ohio, USA.
Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Maternidade do Hospital Estadual Adão Pereira Nunes. Caxias, RJ, Brazil.
University of California. David Geffen School of Medicine. Department of Medicine. Los Angeles, California, USA.
University of California. Department of Obstetrics and Gynecology. David Geffen School of Medicine. Los Angeles, California, USA.
University of California. Department of Obstetrics and Gynecology. David Geffen School of Medicine. Los Angeles, California, USA.
University of California. David Geffen School of Medicine. Department of Pediatrics. Los Angeles, California, USA.
Abstract
Background: There are limited data on how coronavirus disease 2019 (COVID-19) severity, timing of infection, and subsequent vaccination impact transplacental transfer and persistence of maternal and infant antibodies. Methods: In a longitudinal cohort of pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, maternal/infant sera were collected at enrollment, delivery/birth, and 6 months. Anti-SARS-CoV-2 spike immunoglobulin (Ig)G, IgM, and IgA were measured by enzyme-linked immunosorbent assay. Results: Two-hundred fifty-six pregnant women and 135 infants were enrolled; 148 maternal and 122 neonatal specimens were collected at delivery/birth; 45 maternal and 48 infant specimens were collected at 6 months. Sixty-eight percent of women produced all anti-SARS-CoV-2 isotypes at delivery (IgG, IgM, IgA); 96% had at least 1 isotype. Symptomatic disease and vaccination before delivery were associated with higher maternal IgG at labor and delivery. Detectable IgG in infants dropped from 78% at birth to 52% at 6 months. In the multivariate analysis evaluating factors associated with detectable IgG in infants at delivery, significant predictors were 3rd trimester infection (odds ratio [OR] = 4.0), mild/moderate disease (OR = 4.8), severe/critical disease (OR = 6.3), and maternal vaccination before delivery (OR = 18.8). No factors were significant in the multivariate analysis at 6 months postpartum. Conclusions: Vaccination in pregnancy post-COVID-19 recovery is a strategy for boosting antibodies in mother-infant dyads.
Keywords in Portuguese
COVID-19
SARS-CoV-2
Transferência transplacentária
 
Keywords
COVID-19
SARS-CoV-2
Transplacental transfer
 
Citation
CAMBOU, Mary C. et al. Longitudinal Evaluation of Antibody Persistence in Mother-Infant Dyads After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. The Journal of Infectious Diseases, v. 227, n. 2, p. 236-245, Jan 11, 2023.
DOI
10.1093/infdis/jiac366
ISSN
0022-1899